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ABSTRACT
Due to the global spread of multidrug resistant pathogenic bacteria, alternative approaches in
combating infectious diseases are required. One such approach is the use of probiotics.
Lactobacillus fermentum 3872 is a promising probiotic bacterium producing a range of antimicrobial
compounds, such as hydrogen peroxide and lactic acid. In addition, previous studies involving
genome sequencing and analysis of L. fermentum 3872 allowed the identiﬁcation of a gene
encoding a cell surface protein referred to as collagen binding protein (CBP) (not found in other
strains of the species, according to the GenBank database), consisting of a C-terminal cell wall
anchor domain (LPXT), multiple repeats of ‘B domains’ that form stalks presenting an “A domain”
required for adhesion. In this study, we found that the CBP of L. fermentum 3872 binds to collagen I
present on the surface of the epithelial cells lining the gastrointestinal tract. Moreover, we found
that this host receptor is also used for attachment by the major gastrointestinal pathogen,
Campylobacter jejuni. Furthermore, we identiﬁed an adhesin involved in such interaction and
demonstrated that both L. fermentum 3872 and its CBP can inhibit binding of this pathogen to
collagen I. Combined with the observation that C. jejuni growth is affected in the acidic
environment produced by L. fermentum 3872, the ﬁnding provides a good basis for further








Campylobacter jejuni is an enteric pathogen and one of
the most common causes of gastroenteritis in humans
with symptoms such as abdominal pains, watery or
bloody diarrhea, and fever.1 In rare cases, C. jejuni infec-
tions can lead to a neurodegenerative disease such as
Guillain-Barre syndrome.2 C. jejuni infections are often
caused by poor hygiene standards, consumption of
undercooked meat, contaminated water and/or milk.3
Fatalities associated with C. jejuni infections are uncom-
mon, although can occur among immunologically na€ıve
patients.4 C. jejuni infections are an economic burden
leading to many hospitalisations/primary care visits.5
There has been a rise in antimicrobial resistant forms
of C. jejuni caused by the misuse of antimicrobials.6 C.
jejuni has also been placed on a list of antibiotic-resistant
priority pathogens by the world health organization
(WHO) to promote research and development in novel
antimicrobials.7 Due to the appearance of multidrug
resistant forms of these bacteria, there is growing interest
in alternative approaches to combat C. jejuni infections,
such as those using probiotics, bacteriocins and bacterio-
phages, with the most recent focus on probiotics.1 Effec-
tive usage of the latter requires a better understanding of
the molecular mechanisms of their action. The antago-
nistic activity of probiotics is associated with the produc-
tion of bacteriocins, lactic acid, hydrogen peroxide,
competition for nutrients and colonisation niches, as
well as modulation of host immune response.1,8
Lactobacillus fermentum 3872 is a Gram-positive, fac-
ultative anaerobe isolated from milk of a healthy
woman.9 L. fermentum 3872 produces lactic acid and
hydrogen peroxide and is capable of binding to human
HeLa and buccal cells.9 Genome sequencing of L. fer-
mentum 3872 revealed genes required for bacterial sur-
vival in the gastrointestinal tract, as well as those
potentially involved in interaction with ﬁbronectin,
mucin and collagen, such as the genes encoding enolase
and 2 collagen binding proteins.10,11 The full and partial
copies of the collagen-binding protein (CBP) encoding
genes were found to be located on a plasmid and chro-
mosome respectively.10,11 Collagen I, which is one of
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several types of collagens ubiquitous in mammals, is
commonly found on the surface of host cells present in
the gastrointestinal tract.12 In this study, we conﬁrmed
the afﬁnity of the putative CBP of L. fermentum 3872 to
collagen I and found that both CBP and L. fermentum
3872 compete with C. jejuni for binding to this host cell
receptor. In addition, a role of C. jejuni ﬂagellum in
binding to collagen I was established.
Results
The puriﬁed CBP of L. fermentum 3872 interferes
with Campylobacter binding to collagen I
Expression of the L. fermentum 3872 CPB in E. coli as a
His-tagged fusion protein allowed its puriﬁcation as a
stable product of an expected size (111 kDa predicted,
115 kDa estimated from a gel, Fig. S1). The slight (3.6%)
difference in the sizes is likely to be due to conforma-
tional properties of the protein, which is typical for large
outer membrane proteins of bacteria.13 It was found that
the CBP binds to collagen I in a concentration-depen-
dent manner with no increase in absorbance above
0.1 mg/well of CBP (Fig. 1). Since C. jejuni strains
11168H and 81–176 were also able to bind to collagen I
in a concentration-dependent manner (Fig. 2), we aimed
to establish if these bacteria compete with the puriﬁed
CBP for the binding sites.
Inhibition of C. jejuni attachment to collagen I was
detected when using 2 mg of CBP per well (Fig. 3). We
were then wondering if a similar inhibition of Cam-
pylobacter could be observed when using whole cells
Figure 1. ELISA experiments showing CBP binding to collagen I;
the data represent 2 biologic repeats each with 3 technical
repeats (n D 6).
Figure 2. Detection of adhesion of C. jejuni strains 81–176 (A) and 11168H (B) to collagen I using ELISA; the data represent 2 biologic
repeats each with 3 technical repeats (n D 6) apart from (A), 2 £ 108 cfu/well, where n D 5.
Figure 3. Effect of CBP (2 mg/well) on adhesion of C. jejuni strains 81–176 (A) and 11168H (B) in binding to collagen I, the bars labeled
‘control’ have respective C. jejuni strains (2 £ 107 cfu/well) only, while that labeled CBP has a mixture of 2 mg CBP and 2 £ 107 cfu/well
C. jejuni; the data represent 3 biologic repeats each with 3 technical repeats (n D 9).
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of L. fermentum. As expected, the inhibition was
observed when using high Lactobacillus/Campylobacter
cell ratios (Fig. 4). Surprisingly, some increase in
C. jejuni binding was seen when using smaller
amounts of L. fermentum 3872 (Fig. 4). As described
in the discussion section, this could be a result of
aggregation of Campylobacter bacteria.
Identiﬁcation of C. jejuni proteins involved
in collagen I adhesion
While genome sequencing reveals genes encoding poten-
tial collagen binding proteins of L. fermentum 3872, one
of which was the subject of this study, no such proteins
could be identiﬁed in the genomes of C. jejuni strains
11168H and 81–176. Therefore, attempts to identify
such proteins were undertaken by using afﬁnity binding
followed by mass spectrometry (LC MS/MS). The analy-
sis of the proteins bound to magnetic beads coated with
collagen I revealed 2 major bands (65 kDa and 15 kDa,
Fig. 5) in both strains tested
Analysis of these bands using mass spectrometry
identiﬁed the top (65 kDa) bands in both strains as ﬂa-
gellin subunits (FlaA and FlaB). Larger observed sizes of
these proteins, when compared with those predicted
from their amino acid sequences (60 kDa), are likely to
be a result of O-linked glycosylation.14 Indeed, it was
reported that the molecular mass of ﬂagellin of strain
81–176 as determined by gel electrophoresis was about
65 kDa, larger than that was predicted from its amino
acid sequence.15 Slight difference in gel mobilities
between ﬂagellins from these 2 strains, as observed in
Fig. 5 can also be explained by strain to strain variation
in glycosylation pattern.
L. fermentum 3872 inhibits C. jejuni growth
by production of acidic environment
Cell-free supernatants of L. fermentum inhibited the
growth of C. jejuni (Fig. 6). Adjustment of the superna-
tant pH (normally about 4.2) to 6.3 abolished inhibition
zone, suggesting that it was the acid environment that
was causing the inhibitory effect. Acidiﬁcation of the
Figure 4. Competition between. L. fermentum 3872 and C. jejuni strains 81–176 (A) and 11168H (B) for binding to collagen I detected
using ELISA, the bars labeled ‘control’ have respective C. jejuni strains of amount 2 £ 107 cfu/well added only, the ratios indicated on
the graph are based on cell to cell amounts added to each well; the data represent 2 biologic repeats each with 3 technical repeats
(n D 6). Control (B) and 1:10 (B) represent data with 3 biologic repeats each with 3 technical repeats each (n D 9).
Figure 5. Silver staining of C. jejuni Co-IP eluate; 1, pre-stained
ladder (Page ruler plus); 2, 11168H eluate after 1 hour incubation;
3, 11168H eluate after 3 hour incubation; 4, 81–176 eluate after
1 hour incubation; 5, 81–176 eluate after 3 hour incubation.
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media is commonly attributed to the release of lactic acid
by these bacteria. On the other hand, heat treatment had
no effect on the inhibition zone (Fig. 6) indicating the
absence of heat labile compounds involved in growth
inhibition. The results suggest that the main anti-
Campylobacter activity is associated with acidiﬁcation of
the environment.
Discussion and conclusion
The results of this study suggest that L. fermentum and
Campylobacter jejuni may exploit the same host cell
receptor for attachment and colonisation. We demon-
strated the molecular mechanism of such interaction and
identiﬁed the adhesins required for binding of these bac-
teria to collagen receptor. As adhesion is important for
C. jejuni host colonisation and infection,16 competition
for adhesion to collagen I may be a viable means of
reducing pathogen load in hosts and thus preventing C.
jejuni infection. Interestingly, whole cell ELISA experi-
ments indicated an increase in absorbance of C. jejuni
being detected when using lower amounts of L. fermen-
tum 3872. Potential reasoning for the latter observation
could be explained by possible auto-aggregation of C.
jejuni or co-aggregation between C. jejuni and L.
fermentum 3872. Co-aggregation between C. jejuni and
other species of Lactobacilli has previously been
reported.17 In vitro experiments demonstrated that the
presence of probiotics can lead to co-aggregation with C.
jejuni and inhibition of adhesion of the latter to human
epithelial cells.18
The ability of probiotic bacteria to cause aggregation
of (or co-aggregation with) C. jejuni cells and inhibit
their binding to host cells may work synergistically with
other antibacterial factors. In particular, higher gastric
acidity was found to reduce the likelihood of C. jejuni
infection.19 This is supported by our study demonstrat-
ing that acidiﬁcation of the environment caused by
Lactobacillus fermentum represents a strong antibacterial
factor. Co-aggregation may further assist in the antago-
nistic action of lactobacilli by reducing the distance
between the probiotic cells and the pathogen.17 Utiliza-
tion of multiple antagonisitic factors would elevate the
effect of probiotics in inhibiting a pathogen, and reduce
the risk of developing of antimicrobial resistance.
According to our data, C. jejuni ﬂagellin binds to
collagen I, supporting other data on the role of ﬂagella in
adhesion.20,21 To our knowledge, this is the ﬁrst study on
the identiﬁcation of a host cell molecule speciﬁcally
interacting with bacterial ﬂagellum. The latter is known
to be modiﬁed by O-linked glycosylation, which is vari-
able in the same strain and is also strain-dependent.22-24
Due to the extreme variability of O-linked ﬂagella
modiﬁcations and the difference between the oligosac-
charide structures decorating ﬂagellins in the 2 strains
tested, the involvement of sugar residues in binding to
collagen seems unlikely.
It would be interesting to investigate other putative
L. fermentum 3872 adhesins predicted from its genome
sequence,11 such as enolase, mucus and ﬁbronectin bind-
ing proteins, as well as aggregation substance precursor.
The results of this study warrant further investigation of
antagonistic activity of this strain in poultry. Due to its
anti-campylobacter activity L. fermentum 3872 could
potentially be used for prophylaxis of such C. jejuni
induced diseases as traveler’s diarrhea, inﬂammatory
bowel disease and irritable bowel syndrome.25,26
Although it was isolated from human milk of a healthy
person9 and is predicted to be generally safe, trial experi-
ments are required to conﬁrm its safety. Adhesion
experiments using epithelial cell lines could be per-
formed to determine competition between CBP or
L. fermentum 3872 and C. jejuni. Furthermore, due to
the presence of other genes encoding putative collagen-
binding proteins such as enolase, cbp gene knockout
experiments could be performed to determine the extent
to which CBP plays a role in collagen adhesion for
L. fermentum 3872. The experiments described in this
Figure 6. Inhibition of growth of C. jejuni strains 81–176 (A) and
11168H (B) in the presence of cell-free L. fermentum 3872 culture
supernatant; 1, M.R.S broth (control); 2–4, L. fermentum 3872 cell-
free supernatant; 2, untreated; 3, heat-treated; 4, pH adjusted.
Three biologic repeats were performed.
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study may also be conducted with other pathogenic bac-
teria, such as e.g. Staphylococci which utilize adhesion to
collagen for host colonisation.27 With an increasing
understanding of the mechanisms of interaction and
competition between bacteria, a wide variety of tools
may be developed for anti-microbial purposes, reducing
our dependence on antibiotics and widening our means
in combatting pathogenic bacteria such as C. jejuni.
Materials and methods
Bacterial strains and growth conditions
L. fermentum 3872 was grown overnight at 37C under
anaerobic conditions on de Man, Rogosa and Sharpe (M.
R.S.) agar (Oxoid), and in M.R.S broth (Oxoid). C. jejuni
11168H is a hypermotile derivative of C. jejuni NCTC
11168 originally isolated from human faeces.22 C. jejuni
81–176 is a highly virulent strain isolated from raw
milk.28 C. jejuni was grown for 24 hours at 37C in a
microaerobic incubator (Don Whitley Scientiﬁc) in an
atmosphere of 10% CO2, 5% O2, N2 85% on CBA
(Columbia Blood Agar Base, Oxoid) supplemented with
5% deﬁbrinated horse blood (Oxoid) and Campylobacter
selective supplement Skirrow (Oxoid). E. coli was grown
at 37C overnight on LB (Luria Bertani) agar (Fisher Sci-
entiﬁc) or in LB broth (Fisher Scientiﬁc) supplemented
with chloramphenicol at 25 mg/ml where appropriate,
e.g., for expression of CBP (see below).
Cloning and puriﬁcation of CBP
The cbp gene lacking the region corresponding to the






primer contained a Shine-Dalgarno (SD) sequence, as
well as a region encoding a hexa histidine tag. Polymerase
chain reaction (PCR) was conducted by using a Q5 High-
Fidelity DNA Polymerase kit (NEB) with the following
conditions: 98C for 30 seconds for initial denaturation,
25 cycles of denaturation for 10 seconds at 98C, anneal-
ing for 30 seconds at 55C and extension for 4 minutes at
55C, and a ﬁnal extension at 72C for 2 minutes.
The PCR product was puriﬁed using the QIAquick
PCR puriﬁcation kit (Qiagen), digested with enzymes
XbaI and SphI (NEB) and cloned into expression vector
pBAD3329 using Quick Ligation kit (NEB) and E. coli
Express competent cells (NEB).
Sanger sequencing, conducted by GENEWIZ revealed
no errors in the cloned fragment.
For protein expression, 10 ml of the overnight culture
of bacteria containing the recombinant plasmid were
inoculated into 250 ml of media, incubated at 37C on a
shaker at 120 rpm to OD600 of 0.6 and induced with
L-arabinose (ACROS organics) at a ﬁnal concentration
of 0.1% for 3 hours. The protein was puriﬁed using a
Clonetech His60 protein puriﬁcation column. The con-
centration of protein was determined using a Pierce BCA
protein assay kit.
Samples were analyzed on NuPAGE Novex 4–12%
Bis-tris gel (ThermoFisher Scientiﬁc) after mixing
with1X NuPAGE LDS sample buffer (ThermoFisher Sci-
entiﬁc) and incubation at 70C for 10 minutes, as recom-
mended by the manufacturer. Electrophoresis was
conducted using 1X NuPAGE MOPS SDS running
buffer (ThermoFisher Scientiﬁc) for 1 hour at 150 V.
The samples were stained using Invitrogen Coomassie
Simply Blue Safe stain (ThermoFisher Scientiﬁc). Equiv-
alent amounts of samples in relation to the number of
cells were loaded onto each well. Silver staining was con-
ducted using the Pierce silver stain kit for mass spec-
trometry (ThermoFisher Scientiﬁc) according to the
standard manufacturer’s protocol. The molecular marker
used for Coomassie staining was PageRuler Plus Pre-
stained protein ladder (ThermoFisher Scientiﬁc) diluted
to 1:10 in 1X NuPAGE LDS buffer (ThermoFisher Scien-
tiﬁc). For Silver staining the PageRuler Plus Prestained
protein ladder (ThermoFisher Scientiﬁc) was diluted
to 1:100 in 1X NuPAGE LDS buffer (ThermoFisher
Scientiﬁc).
Enzyme-linked immunosorbent assay
Calf skin collagen I (Sigma) was dissolved in 0.1M acetic
acid (Fisher Scientiﬁc) to a stock concentration of 1 mg/
ml. Transparent Corning Costar 96 well ﬂat bottom
non-treated polystyrene plates were coated with 0.36 mg/
well calf skin collagen I (Sigma) or BSA (Sigma) in
ELISA coating buffer (0.19 g Na2CO3, 0.37 g NaHCO3 in
125 ml dH2O; pH 9.6). The plates were incubated at
4C overnight. For washing steps, 200 ml/well PBS with
0.1%Tween 20 (PBST) was used. After coating, the plates
were washed twice with PBST and blocked for 1 hour at
room temperature with 2% BSA (Sigma) in PBS
(200 ml/well). Wells were washed 3 times with PBST and
100 ml/well of samples were added to each well. The
plates were incubated at 37C for 1 hour. If bacteria were
used, the samples were incubated under anaerobic condi-
tions. Wells were washed 4 times with PBST. One
hundred microliters of the primary antibody (1:1000
dilution in PBS containing 0.05% Tween20 (Sigma) and
1 mg/ml BSA (Sigma)) were added to each well and the
plates were incubated at 37C for 1 hour. Wells were
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washed 4 times with PBST and 100 ml of an appropriate
secondary antibody (1:1000 dilution in PBS containing
0.05% tween 20 (Sigma) and 3% BSA (Sigma)) was
added, followed by incubation for 1 hour at 37C. Wells
were washed 4 times with PBST and incubated with
a 100 ml of 3,30,5,50-Tetramethylbenzidine substrate
(Sigma) for 15 minutes. Fifty ml/well of 1M H2SO4 were
added to stop the reaction. Absorbance was measured at
450 nm using a Tecan Inﬁnite M200 Pro microplate
reader.
For C. jejuni binding and CBP/C.jejuni competition
assays, Campylobacter jejuni monoclonal primary anti-
body (Bio-Rad) and goat anti-mouse polyclonal second-
ary antibody (Bio-Rad) were used. For CBP binding
assay, Pierce 6x-His Epitope Tag monoclonal primary
antibody (ThermoFisher Scientiﬁc), and anti-mouse IgG,
HRP-linked Polyclonal secondary antibody (Cell Signal-
ing Technology) were used.For whole cell competition
assay anti-Campylobacter jejuni (PEB1), polyclonal
primary antibody (Antibodies-Online) and Goat-anti-
rabbit IgG polyclonal secondary antibody HRP conjugate
(SAB) were used.
Binding and competition assay
For binding assay, CBP stock was diluted in PBS.
The samples were added to collagen I coated wells. BSA-
coated wells were used as negative controls. For C. jejuni
attachment studies the wells coated with collagen I were
incubated with a 100 ml of bacterial suspensions made to
an OD600 of 1, 0.1 and 0.01 in PBS. The ﬁnal amounts of
C. jejuni cells added to each well were 2 £ 108 cfu/well,
2 £ 107 cfu/well and 2 £ 106 cfu/well respectively. BSA-
coated wells were used as negative controls. For whole
cell competition assay, L. fermentum 3872 bacterial sus-
pension was made to an OD600 of 0.5 (1 £ 108 cfu/ml),
1 (2 £ 108 cfu/ml), 5 (1 £ 109 cfu/ml), and 9 (2 £ 109
cfu/ml) by mixing with C. jejuni to have a ﬁnal bacterial
suspension of OD600 0.1 (2 £ 108 cfu/ml) in PBS. A hun-
dred microliters of the mixture was added to each well.
This resulted in a ﬁnal ratio of L. fermentum 3872 to
C. jejuni of 1:2, 1:1, 5:1 and 10:1 respectively. For compe-
tition assays involving CBP and C. jejuni, collagen I or
BSA coated wells were incubated with a mixture of
2 mg/well CBP and 2 £ 107 cfu/well C. jejuni in PBS.
Agar well diffusion assay
Agar well diffusion assay was used to determine anti-C.
jejuni activity.18 C. jejuni suspensions were adjusted to
an OD600 of 1 in PBS, of which 300 ml were added to
15 ml of soft (0.75%) Mueller-Hinton (MH) agar at
41C. Soft agar was prepared by mixing MH broth
(Fluka) to 0.75% agar (Fluka). The inoculated molten
agar was overlaid over 20 ml MH agar. L. fermentum
3872 was cultured overnight in M.R.S broth at 37C
under anaerobic condition and ﬁlter sterilised using a
0.22 mm ﬁlter (Fisher Scientiﬁc). The cell-free culture
supernatant was either boiled at 100C for 5 minutes, or
the pH was adjusted to that of the M.R.S broth (6.3)
using NaOH (Sigma). Four 10 mm wells were cut in the
MH agar after inoculating with C. jejuni. The wells were
ﬁlled with 300 ml of one of the following 1) MH broth,
2) cell-free 3872 culture supernatant 3) boiled cell-free
3872 culture supernatant, or 4) cell-free 3872 culture
supernatant with adjusted pH.
Co-Immunoprecipitation and mass spectrometry
Co-Immunoprecipitation (Co-IP) was conducted using
Dynabeads Co-Immunoprecipitation kit (ThermoFisher
Scientiﬁc) to determine collagen I binding proteins
expressed by C. jejuni 11168H and 81–176. Dynabeads
were coated with 15 mg of collagen I (15 mg of collagen
per 1 mg of Dynabeads). Standard manufacturer’s proto-
col was followed. C. jejuni suspension was made to an
OD600 of 1 in 20 ml of PBS. The cell suspension was
spun down at 3200 g for 10 minutes at 4C, the superna-
tant was removed and the bacteria pellet was weighed.
Lysis buffer was prepared using 1X IP buffer provided by
the Dynabeads Co-Immunoprecipitation kit (Thermo-
Fisher Scientiﬁc), 100mM NaCl (Sigma) and 5 ml DNase
I (Promega) in dH2O. The bacterial pellet was lysed in a
1:9 ratio of cell weight to volume and incubated on ice
for 10 minutes. To ensure complete lysis, bacterial lysates
were sonicated (Soniprep 159) for 10 cycles with 10 sec-
onds sonication and 30 seconds rest, to complete lysis.
After sonication, the samples were spun at 3200 g for
5 minutes. The clariﬁed lysates were incubated at room
temperature with 2 mg of collagen I coupled Dynabeads
on a rotator (30 rpm) for 1 and 3 hours. Standard manu-
facturer’s protocol was followed for protein elution.
Prior to mass spectrometry, Pierce silver stain kit
(ThermoFisher Scientiﬁc) was used to detect protein
bands (see above). Bands were cut out using a scalpel
and placed into an Eppendorf tube with 50 ml of dH2O.
Mass spectrometry was conducted by the Cambridge
Center for Proteomics (United Kingdom). Mascot server
was used for the identiﬁcation of proteins using Genbank
data of the respective C. jejuni strains.
Statistical analysis
ELISA readings were adjusted by subtracting values of rele-
vant controls. Statistical analysis was conducted using one-
way analysis of variance (ANOVA). A P value of < 0.05
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was considered as statistically signiﬁcant. On ELISA graphs
the P variances are labeled by stars according to the follow-
ing scheme:  for 0.005<p 0.05,  for 0.001<p
0.005 and  for p 0.001. The vertical bars on the dia-
grams represent SEMs (standard errors of the mean).
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